Swedish drug development services provider Inhalation Sciences Sweden has been acquired by a consortium comprising Per Gerde, Fredrik Sjovall, and Rasunda Forvaltning.

"With the aim of further expanding its presence in the US, Quotient Clinical has acquired US-based contract development and manufacturing services provider, QS Pharma."

Per Gerde is the founder of the target company, whereas Fredrik Sjovall is its CEO.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The stake was sold by KDev Investments, an investment firm held jointly by Karolinska Development and Rosetta Capital.

With the aim of further expanding its presence in the US, Quotient Clinical has acquired US-based contract development and manufacturing services provider, QS Pharma.

Based in the UK, Quotient Clinical provides drug development services. The acquisition has been made from Charles River Laboratories International, a US-based pre-clinical and clinical laboratory services provider.

See Also:

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.